Medicare announces price cuts for 15 prescription drugs, including Ozempic

The Centers for Medicare & Medicaid Services (CMS) on Tuesday announced negotiated price reductions for 15 high‑cost outpatient prescription drugs under Medicare, including Ozempic and Wegovy. The cuts come via the drug price negotiation program established by the Inflation Reduction Act, signed by President Joe Biden in 2022, and will take effect in 2027. CMS estimates the negotiated discounts will save taxpayers roughly $12 billion and reduce Medicare enrollee out‑of‑pocket spending by about $685 million that year. This is the second round of mandatory negotiations after last year’s agreements covering 10 drugs, which are scheduled to begin in 2026.

Key Takeaways

• CMS announced lower negotiated prices for 15 drugs, including Ozempic and Wegovy, with the new prices effective in 2027.
• The negotiated 30‑day price for Ozempic, Rybelsus and Wegovy is $274, down from a 2024 list price of $959; higher Wegovy doses negotiated at $385.
• CMS projects the program will save taxpayers about $12 billion and cut Medicare enrollee out‑of‑pocket costs by $685 million in 2027.
• The 15 drugs represented $42.5 billion, or 15%, of Medicare Part D spending in 2024, according to CMS figures.
• Drugmakers may opt out of the program, which could lead them to withdraw products from Medicare — risking access to one of the largest payer markets.
• This negotiation authority stems from the Inflation Reduction Act (2022); previous administration approaches, including the Trump-era “most favored nation” strategy, rely on executive actions and voluntary arrangements.

Background

The Medicare drug price negotiation program was created by the Inflation Reduction Act of 2022 to allow CMS to set maximum payment amounts for selected high‑spending Part D medications. The law targets medicines that account for a large share of Medicare drug spending and phases in negotiated prices across two-year implementation cycles. Last year the administration completed its first set of negotiations covering 10 drugs, with those price reductions slated to begin in 2026; this 2027 cohort is the program’s second round.

The program differs from earlier executive‑branch efforts that sought lower prices through administrative orders or voluntary industry deals. Critics and some manufacturers have challenged the law in court; so far, legal challenges have not blocked implementation. Stakeholders — including payer advocates, patient groups and pharmaceutical companies — are closely watching how negotiated prices affect market access, manufacturer revenues, and patient affordability.

Main Event

On Tuesday CMS released the negotiated 30‑day prices and the corresponding 2024 list prices for 15 drugs used for conditions ranging from diabetes and obesity to cancer and respiratory disease. The list includes high‑profile products such as Ozempic, Wegovy and Rybelsus, where the negotiated price is $274 versus a 2024 list price of $959 for a 30‑day supply. For some medicines the reductions are substantial — e.g., Xtandi falls to $7,004 from $13,480 and Pomalyst to $8,650 from $21,744.

The agency framed the action as part of broader efforts to lower health care costs for Medicare beneficiaries and taxpayers. CMS noted the negotiated prices are the amounts Medicare will pay manufacturers; they do not directly set beneficiary copays, though lower Medicare payments typically feed through to reduced patient costs over time. CMS also provided estimates of program savings: about $12 billion for taxpayers and $685 million in reduced enrollee out‑of‑pocket costs in 2027.

Some manufacturers will face a choice: accept the negotiated maximum payment or decline participation, which would likely lead to exclusion from Medicare Part D. Industry legal challenges to the program have so far failed to prevent implementation, but the risk of market withdrawal remains a bargaining lever for drugmakers evaluating their options.

Analysis & Implications

These negotiated price cuts mark a substantive shift in how Medicare interacts with high‑cost outpatient medicines. By using a statutory negotiating authority, CMS can compel lower net payments from manufacturers for selected products — a change from prior reliance on market forces or voluntary discounts. Over time, expanded use of negotiation could alter pricing benchmarks across private insurance and employer plans, since Medicare prices often anchor broader market expectations.

For beneficiaries, the effect on out‑of‑pocket spending will depend on plan benefit design and how Part D sponsors adjust formularies and cost‑sharing tiers. CMS projects $685 million in out‑of‑pocket savings for enrollees in 2027, a modest portion of overall drug spending but meaningful for patients who regularly use these medicines. Policy analysts note that negotiated prices are what Medicare pays manufacturers; the pass‑through to individual patients will vary by plan structure and supplemental coverage.

Manufacturers face tradeoffs. Accepting a negotiated price preserves access to Medicare’s large patient population but reduces revenue per unit; declining could preserve list prices in other channels but risks losing Medicare market share. The political implications are also evident: pricing decisions remain a flashpoint in national debates over health care costs and pharmaceutical innovation incentives.

Comparison & Data

The 15 medicines named for negotiation accounted for $42.5 billion of Part D spending in 2024, or roughly 15% of the program’s total outpatient prescription drug expenditure. The table highlights the magnitude of reductions — in several cases cutting list prices by 40–60% or more — and shows how concentrated spending on a relatively small set of products has been within Part D.

Reactions & Quotes

Officials from CMS and Health and Human Services framed the announcement as an important step toward affordability, while some policy experts welcomed the relief to taxpayers and beneficiaries and noted unresolved operational questions.

“President Trump directed us to stop at nothing to lower health care costs for the American people,” said Secretary Robert F. Kennedy Jr., linking the move to broader cost‑reduction goals.

Robert F. Kennedy Jr., HHS (official statement)

This statement was included in the administration’s release and positions the negotiation action within a wider political commitment to lower costs for seniors, even as the program is rooted in bipartisan legislation enacted under the previous administration.

“The price negotiations look very reasonable to me. It should hopefully provide some relief for taxpayers and beneficiaries in the long run,” said Stacie Dusetzina, a health policy professor at Vanderbilt University.

Stacie Dusetzina, Vanderbilt University (academic)

Dusetzina also noted the negotiated $274 price for Ozempic and Wegovy is higher than a reported $250 figure tied to a separate voluntary deal, underscoring debate over whether voluntary or statutory approaches produce deeper savings for Medicare.

Unconfirmed

• Whether all affected manufacturers will accept the negotiated prices: some may decline, but specific withdrawal plans have not been publicly confirmed by companies.
• The exact pass‑through of negotiated Medicare payment reductions to individual beneficiary copays will vary by plan and has not been fully determined for each Part D sponsor.
• Comparisons between the negotiated Ozempic/Wegovy price ($274) and the separate voluntary deal price ($250) hinge on differing terms and scopes; public details of commercial agreements remain incomplete.

Bottom Line

CMS’s announcement marks a significant implementation milestone for the drug price negotiation program created by the Inflation Reduction Act. The negotiated reductions — particularly for high‑profile products like Ozempic and Wegovy — are likely to lower Medicare’s bill for these medicines and provide measurable but partial relief to beneficiaries starting in 2027.

The longer‑term effects will depend on manufacturer responses, Part D plan design adjustments and broader market reactions. Policymakers, patient advocates and industry participants will watch whether negotiated prices spur similar movements in private markets or prompt legal and commercial countermeasures that reshape access and affordability.

Sources

• NBC News — news report summarizing CMS announcement and expert reaction